WO2010006189A3 - Small-molecule inhibitors of hif and angiogenesis - Google Patents

Small-molecule inhibitors of hif and angiogenesis Download PDF

Info

Publication number
WO2010006189A3
WO2010006189A3 PCT/US2009/050137 US2009050137W WO2010006189A3 WO 2010006189 A3 WO2010006189 A3 WO 2010006189A3 US 2009050137 W US2009050137 W US 2009050137W WO 2010006189 A3 WO2010006189 A3 WO 2010006189A3
Authority
WO
WIPO (PCT)
Prior art keywords
hif
angiogenesis
small
molecule inhibitors
inhibitors
Prior art date
Application number
PCT/US2009/050137
Other languages
French (fr)
Other versions
WO2010006189A2 (en
Inventor
Erwin G. Van Meir
Kyriacos Nicolaou
Original Assignee
Emory University
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University, The Scripps Research Institute filed Critical Emory University
Publication of WO2010006189A2 publication Critical patent/WO2010006189A2/en
Publication of WO2010006189A3 publication Critical patent/WO2010006189A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

Inhibitors of Hypoxia Inducible Factor (HIF) and angiogenesis, for example 2,2-dimethylbenzopyran compounds and derivatives thereof, and methods of their use including treatment of cancer, disorders leading to ischemia (e.g., stroke and ischemic heart disease), and non-cancerous angiogenic diseases are provided.
PCT/US2009/050137 2008-07-11 2009-07-09 Small-molecule inhibitors of hif and angiogenesis WO2010006189A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7994708P 2008-07-11 2008-07-11
US61/079,947 2008-07-11

Publications (2)

Publication Number Publication Date
WO2010006189A2 WO2010006189A2 (en) 2010-01-14
WO2010006189A3 true WO2010006189A3 (en) 2010-04-29

Family

ID=41507743

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/050137 WO2010006189A2 (en) 2008-07-11 2009-07-09 Small-molecule inhibitors of hif and angiogenesis

Country Status (1)

Country Link
WO (1) WO2010006189A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
MX2012006560A (en) 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration.
WO2011133659A2 (en) 2010-04-20 2011-10-27 Emory University Inhibitors of hif and angiogenesis
US9381260B2 (en) 2011-12-27 2016-07-05 Emory University Hypoxia inducible factor-1 pathway inhibitors and uses as anticancer and imaging agents
IL297229A (en) 2012-01-27 2022-12-01 Abbvie Inc Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
WO2016164412A1 (en) * 2015-04-07 2016-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hypoxia-inducible factor 1 (hif-1) inhibitors
WO2020205801A1 (en) * 2019-03-29 2020-10-08 Judith Boston Treating ophthalmic disease using hypoxia-inducible factor inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020008A1 (en) * 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020008A1 (en) * 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
K.C.NICOLAOU ET AL: "Natural Product-like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 122, 30 September 2000 (2000-09-30), pages 9939 - 9953 *
KARSTEN KROHN ET AL: "Isolation and synthesis of chalcones with different degrees of saturation", PHYTOCHEMISTRY, vol. 61, 20 November 2002 (2002-11-20), pages 931 - 936 *

Also Published As

Publication number Publication date
WO2010006189A2 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
WO2010006189A3 (en) Small-molecule inhibitors of hif and angiogenesis
WO2011133659A3 (en) Inhibitors of hif and angiogenesis
WO2010006184A3 (en) Small-molecule inhibitors of hif and angiogenesis
DOP2006000170A (en) NEW DERIVATIVES OF ESPIROCROMANONA
EA201001733A1 (en) DERIVATIVES OF THYENOPYRIDONE AS AMP-ACTIVATED PROTEINKINASE (AMRC) ACTIVATORS
MX2020005645A (en) Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation.
CY1118721T1 (en) DERYDRO-1H-INDEN-1-YL-2,7-DIAZASPIER PRODUCT 2,3-DYN-1H-2,7-DIAZAPEIRO AND USE THEM AS COMPETITORS OR REVERSE COMPONENTS
ECSP12012125A (en) ARILTRIAZOLONAS LINKED TO BISARILO AND ITS USE
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
NO20071243L (en) Substituted biarylpiperazinylpyridine analogs.
WO2009151598A8 (en) Diazacarbazoles and methods of use
DOP2013000125A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS SUBSTITUTED ACIDS AND ITS USE.
EA201071045A1 (en) COMPOUNDS OF OXADIAZOANTHRACENE FOR THE TREATMENT OF DIABETES
NI201200072A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
MA32485B1 (en) PYRIDAZINE DERIVATIVES AS SMO INHIBITORS
NO20080408L (en) Azaindazole Compounds and Their Use
UA102251C2 (en) Aminidihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
GT200600193A (en) IMIDAZOQUINOLINES AS KINASE LIPID INHIBITORS
MX2021014938A (en) Aldose reductase inhibitors and methods of use thereof.
BR112014009910A2 (en) 1- (5,6-Dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt formulations
GT200600109A (en) PYRIMIDINCARBOXILIC ACID DERIVATIVES AND ITS USE
MX2010002565A (en) Substituted 6-pheylnicotinic acids and the use thereof.
WO2010124201A3 (en) Compositions and methods for treatment of cardiovascular disease
WO2013061004A8 (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09795203

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09795203

Country of ref document: EP

Kind code of ref document: A2